The U.S. Food and Drug Administration (FDA) has approved darbepoetin alfa (Aranesp®) for the treatment of anemia related to chemotherapy or chronic kidney failure. The medicine comes in injectable form and is given either subcutaneously or intravenously. It works by stimulating the production of red blood cells in the bone marrow.
Safety information on darbepoetin alfa should be reviewed with your healthcare provider prior to beginning treatment so that you are aware of all the risks. This includes possible side effects, such as diarrhea, muscle pain, and fatigue, and being aware of the drugs that can cause negative interactions.
(Click Darbepoetin Alfa for more information on this drug. Topics covered in this article include whether the medication is available in generic form, what to do if you are pregnant or breastfeeding, and more.)
HealthSavvy Sign In
|